Figure 2 | Scientific Reports

Figure 2

From: RNA editing facilitates the enhanced production of neoantigens during the simultaneous administration of oxaliplatin and radiotherapy in colorectal cancer

Figure 2

ADAR1 is upregulated in CRCs treated with CRT. (A) IHC analysis revealed strong staining for ADAR1 in CRCs treated with CRT. (B) ADAR1 was upregulated in the nucleus of CRT-CRCs relative to the normal mucosa (p < 0.001) and in CRCs without CRT (p < 0.001). (C) ADAR1 was also upregulated in the cytoplasm of CRT-CRCs compared with normal mucosa (p < 0.001) or CRCs without neoadjuvant therapy (p < 0.001). Wilcoxon’s signed-rank test. ***p < 0.001.

Back to article page